LATS1 and hepatocellular carcinoma: Furthermore, altered <i>LATS1</i> was abundantly enriched in the HCC-recurrent group, and impressively, it was independent of clinicopathological features in predicting RFS (median RFS of altered type vs. wild-type: 5.57 months vs. 22.47 months, <i>p</i> < 0.01).